Skip to content
#small language model Open access

MultiTargetDB: a comprehensive database of multitarget ligands for polypharmacology research and drug discovery.

Oct 2026 · Nucleic Acids Research · 0 citations · 25 references
Medicine

TL;DR

A database of multitarget ligands integrated with comprehensive biological annotations and measurement-level provenance, which provides a basis for drug-repurposing exploration, computational modeling, and machine-learning applications.

Abstract

Multitarget drug discovery has gained considerable traction in recent years, particularly for the treatment of complex diseases. Despite the growing demand for dedicated, well-curated resources to advance polypharmacology research and rational multitarget drug discovery, such resources remain severely limited. Here, we present MultiTargetDB, a database of multitarget ligands integrated with comprehensive biological annotations and measurement-level provenance. At the small molecule level, MultiTargetDB integrates chemical structures (including molecular scaffolds), their drug development stages, and target information, whereas at the target level, MultiTargetDB incorporates protein domains and families, functional associations, and pathway-disease annotations. The current release contains 173 977 multitarget molecules, 6496 protein targets, and 474 749 standardized quantitative bioactivity records, complemented by 46 234 high-confidence protein functional associations, 370 pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG), and 2493 diseases. MultiTargetDB supports multitarget ligand retrieval, target-combination analysis, quantitative activity profiling, inspection of source-level evidence, and biological interpretation of molecule-target-pathway-disease relationships, with a natural-language query assistant facilitating flexible database exploration. The integrated quantitative, pharmacological and biological data further provide a basis for drug-repurposing exploration, computational modeling, and machine-learning applications. MultiTargetDB v1.0 is freely accessible at https://multitargetdb.inflygent.com/.

Read PDF

Similar papers

Open access Oct 2026

Polypharmacological target-aware molecule generation

This work reformulates multitarget drug design as a sequence-based generation task and introduces PolyTamGen, an end-to-end autoregressive framework that improves joint success rates over representative baselines while maintaining high chemical validity and diversity.

Ke-Han Wu, Wei Zhang, Han Guo et al. · 0 citations
Oct 2026

A proteome-scale reverse screening approach reveals multi-target interactions of anthraquinone derivatives in cancer-related pathways.

This integrative computational framework combines proteome-scale target discovery, pathway prioritization, structural validation, molecular dynamics, and ADMET evaluation to provide a systems-level perspective on the potential multi-target anticancer mechanisms of anthraquinone derivatives and identify candidate target...

Faezeh Ramezani Pastaky, Hassan Hassani Kumleh, S. Arab et al. · 0 citations
Open access Oct 2026

TTPdb: a comprehensive database of targeted therapeutic peptides.

Targeted therapeutic peptides (TTPs) represent a promising therapeutic modality that bridges the gap between small-molecule drugs and macromolecular antibody-based therapeutics by combining high target specificity, superior tissue permeability, and controllable synthesis. Recent advances in chemical modification and co...

Yang Zhang, Xue-Dong Li, Wei-Min Lu et al. · 0 citations
#machine learning Review Oct 2026

A curated multi-endpoint drug-protein bioactivity dataset with construct-aware protein targets

Crate-DTI, a construct-aware dataset derived from the 1 July 2026 BindingDB export, with IC50, Ki, Kd and EC50 processed independently, supports endpoint-specific classification and regression while allowing users to select molecular representations, protein representations and evaluation splits.

Lina Abou-Abbas, Nour Mhanna, Hasan Bazzi et al. · 0 citations
Review Oct 2026

AlphaFold-driven structure-based drug discovery: Capabilities, benchmarks and limitations for medicinal chemistry.

This review covers the aspects of SBDD approach, traditional methods of protein structure determination and limitations that have restricted the application of this methodology, and addresses the use of AlphaFold models in major drug discovery processes including target identification, binding site prediction, molecula...

M. Pathak · 0 citations
Open access Oct 2026

drugMR: A multi-omics pipeline for genetically anchored drug-target discovery

DrugMR is a Nextflow pipeline that runs cis-Mendelian randomisation, colocalisation, SMR-HEIDI with bulk and/or single-cell QTLs, three-trait colocalisation and a phenome-wide screen for adverse effects and repurposing, applied to schizophrenia with brain pQTLs.

G. C. Cimadevila, Marie-Joe Dib, M. Bracher-Smith et al. · 0 citations

Related blog posts

Microsoft Research Blog Nov 16, 2026

TokenEconomizer: Learning from Experience to Make AI Coding Agents More Efficient

AI coding agents are increasingly help developers fix bugs and build features largely on their own, but every interaction with their models consumes tokens. In each session, an agent sends instructions, tool descriptions, and session history to its model. Most efforts to reduce this cost focus on individual tasks. Yet developers return to the same […] The post TokenEconomizer: Learning from Experience to Make AI Coding Agents More Efficient appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.